9b308588-5e79-46ab-b186-6edd686695c6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 64.413415468857
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- NOTCH_SIGNALING+0.460
- APICAL_SURFACE+0.410
- APICAL_JUNCTION+0.390
- WNT_BETA_CATENIN_SIGNALING+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- MYOGENESIS+0.370
- HEDGEHOG_SIGNALING+0.350
- ANGIOGENESIS+0.320
- COAGULATION+0.320
Top 10 suppressed
- E2F_TARGETS-0.510
- PROTEIN_SECRETION-0.500
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V1-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.380
- MTORC1_SIGNALING-0.360
- ANDROGEN_RESPONSE-0.290
- SPERMATOGENESIS-0.200
- DNA_REPAIR-0.150
- MITOTIC_SPINDLE-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7f51ff28-397d-466f-82b0-25e9c9182ea7 | — | — | 0.936 |
| 2 | SAMN03290902 | — | — | 0.916 |
| 3 | 1652b0a3-dc1d-4490-9632-07673713deb1 | — | — | 0.906 |
| 4 | SRR2689710 | — | — | 0.905 |
| 5 | BS_5P3CZQV8 | Neurofibroma | — | 0.897 |
| 6 | BS_T3H5AY8A | low-grade glioma | — | 0.894 |
| 7 | MDT-AP-1125 | Med | Medulloblastoma | 0.890 |
| 8 | BS_TA9WP4TH | Med | Medulloblastoma | 0.888 |
| 9 | SAMN03290921 | — | — | 0.887 |
| 10 | R89 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.460 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |